Nanobodies, the potent agents to detect and treat the Coronavirus infections: A systematic review.
COVID-19
Nanobodies
SARS-CoV-2
VHH
Journal
Molecular and cellular probes
ISSN: 1096-1194
Titre abrégé: Mol Cell Probes
Pays: England
ID NLM: 8709751
Informations de publication
Date de publication:
02 2021
02 2021
Historique:
received:
19
11
2020
revised:
17
12
2020
accepted:
18
12
2020
pubmed:
29
12
2020
medline:
11
2
2021
entrez:
28
12
2020
Statut:
ppublish
Résumé
The newly emerged coronavirus (SARS-CoV-2) continues to infect humans, and no effective treatment has yet been found. Antibody therapy is one way to control infection caused by COVID-19. However, the use of classical antibodies raises complex issues. Heavy chain antibodies (HCAbs) are single-domain antibodies derived from the Camelidae family. The variable part of these antibodies (Nanobodies or VHH) has interesting properties such as small size, cost-effective production, and good tissue permeability, causing VHH to be regarded as an antiviral therapeutics. However, the small size of nanobodies may lead to low antigen binding affinity and rapid renal clearance. In this systematic review, the application of nanobodies in the treatment of COVID-19 infection and other similar infections (MERS and SARS) was reviewed.
Identifiants
pubmed: 33358936
pii: S0890-8508(20)30581-8
doi: 10.1016/j.mcp.2020.101692
pmc: PMC7832525
pii:
doi:
Substances chimiques
Antibodies, Neutralizing
0
Single-Domain Antibodies
0
Types de publication
Journal Article
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
101692Informations de copyright
Copyright © 2020. Published by Elsevier Ltd.
Références
Hepatology. 2013 Sep;58(3):932-9
pubmed: 23553604
MedComm (2020). 2021 Mar;2(1):101-113
pubmed: 33821254
Antib Ther. 2019 Jan;2(1):1-11
pubmed: 30627698
Int J Biol Markers. 2014 Jun 25;29(2):e169-79
pubmed: 24425321
Nat Struct Mol Biol. 2020 Sep;27(9):846-854
pubmed: 32661423
J Nanobiotechnology. 2020 Sep 5;18(1):125
pubmed: 32891146
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2017 Dec;33(12):1662-1668
pubmed: 29382428
Nat Rev Immunol. 2020 May;20(5):269-270
pubmed: 32273594
Antimicrob Agents Chemother. 2015 Oct 05;60(1):6-13
pubmed: 26438495
Nat Commun. 2020 Sep 4;11(1):4420
pubmed: 32887876
J Virol Methods. 2010 Nov;169(2):282-9
pubmed: 20674610
Biochem Pharmacol. 2018 Dec;158:413-424
pubmed: 30342023
Bioconjug Chem. 2020 Aug 19;31(8):1873-1882
pubmed: 32639742
Nature. 2003 Oct 30;425(6961):915
pubmed: 14586458
JAMA. 2020 May 12;323(18):1824-1836
pubmed: 32282022
Biotechnol Appl Biochem. 2021 Apr;68(2):239-246
pubmed: 32270531
J Virol. 2018 Aug 29;92(18):
pubmed: 29950421
Emerg Infect Dis. 2014 Jun;20(6):1012-5
pubmed: 24857749
Mol Biotechnol. 2013 Oct;55(2):159-67
pubmed: 23666874
Viruses. 2019 Feb 19;11(2):
pubmed: 30791410
Appl Microbiol Biotechnol. 2013 May;97(10):4457-66
pubmed: 23135228
Cell. 2020 May 28;181(5):1004-1015.e15
pubmed: 32375025
Nat Commun. 2020 Sep 10;11(1):4528
pubmed: 32913273
Emerg Microbes Infect. 2020 Dec;9(1):1034-1036
pubmed: 32403995
Sci Adv. 2018 Aug 08;4(8):eaas9667
pubmed: 30101189
Int J Surg. 2010;8(5):336-41
pubmed: 20171303